Wednesday, February 10, 2010, 1:27PM AEST - The Australian Stockmarket closes in 2 hours and 38 minutes.
To create a watchlist or portfolio of shares, Register

Santarus Inc. (SNTS)

8:00AM AEST: 3.70 USD  Down 0.01 (0.27%)  
 MORE ON SNTS 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Santarus, Inc. (NGM:SNTS) Delayed quote dataEdit
Last Trade:3.70 USD
Trade Time: 8:00AM AEST
Change:Down 0.01 (0.27%)
Prev Close:3.71
Open:3.70
Bid:3.13 x 100
Ask:4.27 x 100
1y Target Est:5.50
Day's Range:3.66 - 3.79
52wk Range:1.05 - 5.82
Volume:246,512
Avg Vol (3m):697,211
Market Cap:214.88M
P/E (ttm):N/A
EPS (ttm):-0.05
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add SNTS to Portfolio   Download Data

 HEADLINES 
SANTARUS INC Files SEC form 8-K, Other Events
EDGAR Online (Tue, Feb 2)
SANTARUS INC Files SEC form 8-K, Other Events
EDGAR Online (Sat, Jan 16)
Neutral on Santarus
Zacks.com (Thu, Jan 7)
Santarus Receives $20 Million
Zacks.com (Thu, Dec 31)
Santarus eyes Phase III trials for diarrhea drug
at MarketWatch (Wed, Dec 30)
Santarus Submits IND for Phase III Clinical Testing of Rifamycin SV MMX in Travelers' Diarrhea
Business Wire (Wed, Dec 30)
3 Stocks Ready to Roar
at Motley Fool (Thu, Dec 24)
Santarus Receives Previously Announced $20 Million Milestone for FDA Approval of ZEGERID OTC
Business Wire (Tue, Dec 22)
Santarus Lippert/Heilshorn Life Sciences Call scheduled for 10:30 am ET today
Vcall (Wed, Dec 16)
Santarus Announces Webcast Presentation at the Lippert/Heilshorn Life Sciences Virtual Conference
Business Wire (Tue, Dec 15)
Santarus, JA Solar: Early Volume Plays
at TheStreet.com (Tue, Dec 8)
SANTARUS INC Files SEC form 8-K, Other Events
EDGAR Online (Mon, Dec 7)
More Headlines for SNTS...

 ANALYST 
EPS Est (next year) (Dec-09) :0.33
EPS Est (in 2 years) (Dec-10) :0.28
Avg Rec (current)*:2.5
PEG Ratio:1.30
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Santarus, Inc., a specialty pharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that treat upper gastrointestinal diseases and disorders.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices